Saturday 17 October 2026
Export INBS’s income statement to Excel — free account
Intelligent Bio Solutions Inc.
INBS Healthcare Medical Devices
Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025. In the quarter to June 2026, revenue grew 51.1%, EPS grew 78.1% and free cash flow fell 31.6%, each against the same quarter a year earlier.
1.50
0.06
+4.17%
Follow INBS
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Piotroski F-Score |
5 | 3 | 5 | 2 | 3 | — | — | — | — | — |
Altman Z-Score |
(11.40) | (13.69) | (6.92) | (9.46) | (4.12) | 2.14 | — | — | — | — |
P/S ratio |
0.80 | 2.97 | 0.94 | 1.22 | 4.36 | 20.53 | 0.00 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(25.53) | (33.83) | (14.31) | (22.04) | (8.28) | 1.53 | (43.49) | — | — | — |
P/Operating CF |
(1.06) | (4.10) | (0.99) | (4.80) | (5.62) | (24.16) | (35.56) | — | — | — |
Beneish M-Score |
(2.45) | (2.65) | (2.27) | 0.91 | (4.84) | 20.41 | — | — | — | — |
P/B ratio |
0.64 | 3.22 | 0.36 | 0.76 | 1.48 | 2.71 | 0.00 | — | — | — |
Price to Tangible BV |
1.36 | 0.00 | 0.77 | 0.00 | 1.48 | 2.71 | 0.00 | — | — | — |
EV/Sales |
0.43 | 3.43 | (0.24) | 1.74 | 1.93 | 15.24 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(0.15) | (1.08) | 0.08 | (0.54) | (1.28) | (2.67) | (29.98) | — | — | — |
EV/FCF |
(0.15) | (1.04) | 0.08 | (0.51) | (1.28) | (2.67) | (29.98) | — | — | — |
Quick Ratio |
1.15 | 0.44 | 1.33 | 0.40 | 2.17 | 4.26 | 0.06 | 0.05 | 0.08 | 0.01 |
Current Ratio |
1.44 | 0.77 | 1.57 | 0.66 | 2.33 | 4.94 | 0.30 | 0.05 | 0.09 | 0.01 |
Net Debt/EBITDA |
0.35 | 0.11 | 0.41 | (0.16) | 0.65 | 1.88 | (1.65) | 0.00 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 18.05% | 26.47% | 22.96% | 9.60% | 207.37% | 220.42% | 193.91% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.30 | 0.74 | 0.43 | 0.14 | (0.98) | (1.11) | (1.11) | (1.06) |
Asset Turnover |
0.42 | 0.28 | 0.26 | 0.18 | 0.03 | 0.16 | 0.08 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.96 | 0.92 | 0.94 | 0.69 | 0.40 | 1.61 | 0.16 | 0.76 | 1.07 | 0.78 |
Capex/Depreciation |
(0.07) | (0.19) | (0.23) | (0.10) | 0.00 | — | — | — | — | — |
Interest Coverage |
(1,178.33) | (406.05) | (61.54) | (56.35) | (1,111.59) | (5.10) | (6.24) | (17.54) | (20.26) | (2.49) |
| (306.76%) | (192.21%) | (171.13%) | (207.80%) | (77.12%) | (144.28%) | 25.43% | 44.82% | 52.84% | 0.00% | |
| (123.13%) | (95.95%) | (84.17%) | (93.64%) | (48.56%) | (57.84%) | (131.73%) | (304.18%) | (402.29%) | 0.00% | |
ROIC |
(606.86%) | (372.07%) | (147.21%) | (160.96%) | (455.43%) | (76.87%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(504.77%) | 1,099.65% | (278.31%) | 798.84% | (125.92%) | (48.45%) | 59.13% | 123.12% | 99.48% | 4.78% |
Average Days of Receivables |
143.34 | 158.91 | 112.02 | 145.05 | 1,572.31 | 575.80 | 37.91 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
79.98% | 78.51% | 53.79% | 25.44% | 881.70% | 193.67% | 311.71% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
249.15% | 292.17% | 297.53% | 402.44% | 1,125.62% | 169.61% | 1,167.51% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.23 | 0.46 | 0.32 | 0.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
4.63% | 7.80% | 7.41% | 13.04% | 0.00% | 0.00% | 0.00% | — | — | — |
Graham Net Nets |
0.13 | (0.14) | 1.01 | (1.00) | 0.52 | 0.28 | 0.00 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(392.17%) | (119.19%) | (345.87%) | (381.24%) | (84.63%) | (17.28%) | (7.92%) | — | — | — |
Free Cash Flow Yield |
(360.81%) | (111.10%) | (335.38%) | (281.29%) | (34.65%) | (27.78%) | (3.34%) | — | — | — |
Revenue per Share |
2.86 | 5.79 | 19.53 | 237.44 | 71.66 | 460.58 | 53.91 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(8.10) | (18.35) | (60.09) | (878.26) | (550.49) | (2,627.09) | (142.46) | (9.23) | (0.45) | (0.02) |
Capex per Share |
(0.06) | (0.44) | (1.39) | (60.13) | (62.33) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(8.16) | (18.79) | (61.48) | (938.39) | (612.82) | (2,627.09) | (142.46) | (9.23) | (0.45) | (0.02) |
Cash per Share |
2.71 | 1.93 | 39.57 | 183.00 | 1,350.54 | 2,924.12 | 122.09 | 0.33 | 0.03 | 0.00 |
Shareholders Equity per Share |
3.59 | 5.34 | 51.37 | 438.93 | 1,073.08 | 3,489.91 | (1,489.94) | (7.64) | (0.36) | (0.49) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.59 | 5.34 | 51.37 | 438.93 | 1,073.08 | 3,489.91 | (1,489.94) | (7.64) | (0.36) | (0.49) |
Free Cash Flow |
(12.01) | (9.91) | (9.79) | (7.88) | (3.74) | (11.30) | (0.50) | (5.58) | (5.38) | (0.24) |
Working Capital |
2.17 | (1.21) | 3.08 | (2.02) | 6.21 | 14.52 | (5.35) | (5.96) | (5.05) | (6.52) |
Capital Expenditures |
(0.09) | (0.23) | (0.22) | (0.51) | (0.38) | — | — | — | — | — |
Net Current Asset Value |
0.45 | (1.30) | 2.94 | (2.80) | 5.06 | 11.35 | (5.35) | (5.96) | (5.05) | (6.52) |
EV/EBIT |
0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.02 | 0.08 | 0.07 | 0.25 | 0.87 | 0.00 | 0.00 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.95 | 4.81 | 1.72 | 7.21 | 0.00 | — | — | — | — | — |
Cash ROIC |
(129.41%) | (258.47%) | (57.69%) | (98.96%) | (21.21%) | (38.06%) | (144.02%) | (781.01%) | (609.96%) | (63.50%) |
Accounts Receivable Turnover |
2.82 | 2.67 | 3.56 | 1.49 | 0.17 | 1.26 | 3.31 | 0.00 | — | — |
Accounts Payable Turnover |
0.50 | 0.58 | 0.78 | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
4.11 | 2.56 | 1.92 | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
696.25 | 916.53 | 368.98 | 1,024.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
70.57 | 128.40 | 168.30 | 384.50 | — | — | — | — | — | — |
Average Receivables |
1.49 | 1.14 | 0.87 | 1.34 | 2.50 | 1.57 | 0.06 | 0.07 | — | — |
Average Payables |
4.33 | 3.12 | 2.16 | 2.12 | 1.55 | 1.13 | 0.84 | 0.53 | 0.25 | — |
Average Inventory |
0.53 | 0.71 | 0.88 | — | — | — | — | — | — | — |
Average Assets |
10.10 | 11.01 | 12.07 | 11.35 | 17.11 | 12.17 | 2.40 | 2.41 | 1.25 | — |
Average Common Equity |
4.05 | 5.50 | 5.94 | 5.12 | 10.77 | 4.88 | (12.44) | (16.37) | (9.50) | — |
Columns are period end dates